PDF-This presentation contains forward-looking statements (including, with

GILENTTO. Forward looking statements may include in particular statements about future events future financial performance plans strategies expectations prospects competitive environment regulation and supply and demand BASF has based these forward looking st Forward looking statements by their nature involve a number of risks and uncertainties that could cause actual results to differ materially from market expectations These risks and uncertainties include but are not limited to our ability to manage g July 2015 Disclaimers Special Note Regarding Forward - Looking Information This presentation contains "forward - looking information" within the meaning of the U . S . Private Securities Litigation R Update . 2014. A RealisticApproach Seminars Conference Presentation . Topics to be Covered by Today’s Session. S. tatement on . S. tandards for . A. ccounting and . R. eview . S. ervices . (SSARS). This presentation contains “forward-looking information” within the meaning of Canadian Securities legislation. Generally, forward-looking statements can be identified by the use of forward-looking terminology such as “scheduled”, “anticipates”, “expects” or “does not expect”, “is expected”, “scheduled”, “targeted”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. Forward-looking statements contained herein include, without limitation, statements relating to mineral reserve estimates, mineral resource estimates, realization of mineral reserve and resource estimates, capital and operating costs estimates, the timing and amount of future production, costs of production, success of mining operations, the ranking of the project in terms of cash cost and production, permitting, economic return estimates, power and storage facilities, life of mine, social, community and environmental impacts, rare metal markets and sales prices, off-take agreements and purchasers for the Company’s products, environmental assessment and permitting, securing sufficient financing on acceptable terms, opportunities for short and long term optimization of the Project, and continued positive discussions and relationships with local communities and stakeholders. Forward-looking statements are based on assumptions management believes to be reasonable at the time such statements are made. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Although Matamec has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. Factors that may cause actual results to differ materially from expected results described in forward-looking statements include, but are not limited to: . Q3 2013 Earnings Call Presentation. Nov 18, 2013. Disclaimer. This presentation does not constitute an offer to sell or issue or the solicitation of an offer to buy or acquire securities of JinkoSolar Holding Co., Ltd. (the “Company”) in any jurisdiction or an inducement to enter into investment activity, nor may it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. . Q1 2013 Earnings Call Presentation. June 7, 2013. Disclaimer. This presentation does not constitute an offer to sell or issue or the solicitation of an offer to buy or acquire securities of JinkoSolar Holding Co., Ltd. (the “Company”) in any jurisdiction or an inducement to enter into investment activity, nor may it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. . This presentation does not constitute an offer to sell or a solicitation of offers to buy Ordinary Shares (the “Securities”). . Although . reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, the contents of this presentation have not been formally verified by Oxford BioMedica plc (the “Company”) or any other person. Accordingly, no representation or warranty, . Telecom & Media Forum . June 15, 2016. Dave Fuller, . Executive . Vice-President and President, TELUS Consumer and Small Business Solutions. Answers . to questions . contain statements about financial and operating performance of TELUS (the Company) and future events, including with respect to future dividend increases and normal course issuer bids through 2019, the 2016 annual targets and guidance, the proposed purchase of MTS by BCE and the transfer of a certain portion of MTS’ postpaid wireless subscribers and retail locations to TELUS (the “Transaction”) and the agreement between TELUS International and Baring Private Equity Asia (the “TI-Baring Transaction”) that are forward-looking. By their nature, forward-looking statements require the Company to make assumptions and predictions and are subject to inherent risks and uncertainties. There can be no assurance that the conditions to closing of the MTS-BCE transaction will be satisfied, including, without limitation, the relevant regulatory approvals or that the conditions to closing of the Transaction will be satisfied or that the associated benefits for TELUS shareholders and customers of the Transaction will be realized or that the Transaction will occur on the terms contemplated in this . CORPORATE PRESENTATION. Pharmaceuticals. Q4 2017. This presentation contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein or which are otherwise made by or on behalf of the Company that are not statements of historical facts may be deemed forward‑looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “to,” “plan,” “expect,” “believe,” “anticipate,” “intend,” “could,” “should,” “would,” “estimate,” or “continue,” or the negative or other variations thereof or comparable terminology are intended to identify forward‑looking statements. Shareholders are cautioned that all forward‑looking statements involve risk and uncertainties which may cause results to differ materially from those set forth in the statements. Such risks and uncertainties include, but are not limited to the following: the success of research and development activities and the speed with which regulatory authorizations and product launches may be achieved; government regulation generally; competitive developments; the ability to successfully market products domestically and internationally; difficulties or delays in manufacturing or issues relating to manufacturing capacity; commercial obstacles to the successful introduction of brand products generally; legal defense costs, insurance expenses, settlement costs, and the risk of an adverse decision or settlement relating to product liability, patent protection, governmental investigations, and other legal proceedings; the Company’s ability to acquire and protect patents and other intellectual property both domestically and internationally; the absence of certainty regarding the receipt of required regulatory approval or the timing or terms of such approvals; any changes in business, political and economic conditions; business interruption due to hurricanes or other events outside of the Company’s control.. INVESTOR 3RD QUARTER 2020 NASDAQ: PEBO NASDAQ: PEBO 2 NASDAQ: PEBO Statements in this presentation which are not historical are “forward-looking statements” within the meaning of Section 27 ration with acquisition of DEGI Aberdeen builds on an established presence in Germany and reinforces its position as a leading GI finds the right international partner for its continued growth Aberdee Earlier this year Alterity146s PBT434 was granted Orphan drug designation by the US FDA This designation entitles Alterity to seven years of market exclusivity for the use of PBT434 in the treatment o